Efficacy of tripotassium-dicitrato-bismuthate (TDB) and cimetidine in peptic ulcer disease, a control study of 40 gastric ulcer and 80 duodenal ulcer

Chearanai, O.; Kachintorn, U.; Plengvanit, U.

Journal of the Medical Association of Thailand 70(4): 176-180

1987


ISSN/ISBN: 0125-2208
PMID: 3612003
Document Number: 296567
A control trial in 120 patients with peptic ulceration, 40 with gastric ulcers and 80 with duodenal ulcers, diagnosed endoscopically; 20 with gastric ulcers and 40 with duodenal ulcers were treated with tripotassium-dicitrato-bismuthate (TDB, De-Nol) in the dosage of 480 mg/day given twice daily while the other 20 with gastric ulcers and 40 with duodenal ulcers were treated with cimetidine, 800 mg/day divided into two dosages. At the end of the 8th week both drugs rendered similar results, yielding the healing rate of 85 per cent for gastric ulcer and 95 per cent for duodenal ulcer. For ulcers smaller than 1 cm, results of TDB groups were better than the cimetidine group after 4 weeks, i.e. 60 vs. 37 per cent for gastric ulcer and 83 vs 68 per cent for duodenal ulcer. Follow-up study over a 3 month period rendered a recurrence rate of 15 per cent (9 patients) in the TDB group and 16.6 per cent (10 patients) in the cimetidine group.

Document emailed within 1 workday
Secure & encrypted payments